WO2025068943 - KAT6 INHIBITORS
National phase entry is expected:
Publication Number
WO/2025/068943
Publication Date
03.04.2025
International Application No.
PCT/IB2024/059418
International Filing Date
26.09.2024
Title **
[English]
KAT6 INHIBITORS
[French]
INHIBITEURS DE KAT6
Applicants **
BEONE MEDICINES I GMBH
BEONE PHARMACEUTICAL (SUZHOU) CO., LTD.
Inventors
WANG, Qiuwen
WANG, Yayi
GUO, Yunhang
QIN, Ling
WANG, Yuxi
WANG, Zhiwei
Priority Data
PCT/CN2024/096981
03.06.2024
CN
PCT/CN2023/122071
27.09.2023
CN
PCT/CN2024/074987
31.01.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5787 | |
| EPO | Filing, Examination, Granting | 28116 | |
| Japan | Filing, Examination, Granting | 2763 | |
| South Korea | Filing, Examination, Granting | 3301 | |
| USA | Filing, Examination, Granting | 11440 |
Total:
51,407
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are compounds used as inhibitors of KAT6, or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof. Also disclosed is a pharmaceutical composition comprising a compound disclosed herein, and a method for treating or preventing a disorder or a disease responsive to the inhibition of KAT6 activity in a subject using the same. In some embodiments, the compounds are of formula (I), wherein values for the variables are disclosed herein.[French]
L'invention concerne des composés utilisés en tant qu'inhibiteurs de KAT6, ou un sel pharmaceutiquement acceptable, un analogue deutéré, un N-oxyde ou un tautomère de ceux-ci. L'invention concerne également une composition pharmaceutique comprenant un composé de l'invention, et une méthode de traitement ou de prévention d'un trouble ou d'une maladie en réponse à l'inhibition de l'activité de KAT6 chez un sujet l'utilisant. Dans certains modes de réalisation, les composés sont de formule (I), des valeurs pour les variables étant divulguées dans la description.